Neurology

If primary care clinicians are to meet the cognitive screening demands that are growing with an aging population, they need the sharpest tools in the box, this expert says.

A cognitive health assessment will soon be as routine as taking blood pressure or pulse ox, says neurocognitive researcher David J Libon, PhD. He talks more about that future.

Acoustic variables, like shimmer and jitter, that are typically undetectable in human speech can be detected with tablet technology and serve as biomarkers for mental acuity.

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

Three-year follow-up data from the TRAILBLAZER-ALZ 2 extension trial supported early initiation and limited-duration dosing.

The guideline is the first in a series that will focus on diagnosis, treatment, and care of Alzheimer disease and all other dementias, according to the association.

Linus Health is expanding its AI-powered remote cognitive assessment platform, Anywhere, to expand access to early detection of cognitive impairment.

Your daily dose of the clinical news you may have missed.

Data from Roche presented at AAIC 2025 highlight rapid amyloid clearance with investigational antibody and potential of pTau217 as blood-based rule-in and rule-out test.

In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.

The European Commission is expected to make a final regulatory decision on the anti-amyloid therapy in the coming months, Lilly said.

The brain changes that lead to cognitive and behavioral changes referred to as dementia have multiple potential etiologies; not all dementia is Alzheimer disease.

Your daily dose of the clinical news you may have missed.

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

Swenson focused on the precision afforded by digital tools in assessing human behavior and identifying preclinical signs of cognitive impairment.

Eisai will present four-year safety and efficacy data, real-world use patterns, and findings on a new subcutaneous formulation for maintenance treatment in early Alzheimer disease.

In recognition of World Brain Day, Anna Chodos, MD, discusses why early detection of cognitive decline must become standard practice—and how PCPs can take simple, effective steps to make that happen.

Libon, a professor at the New Jersey Institute for Successful Aging at Rowan University, says the refined approach to cognitive assessment is widely available.

World Brain Day is celebrated on July 22 every year. In recognition Patient Care has summarized 9 notable studies of key interest to primary care for quick review.

Digital latency measures enhance early detection of cognitive decline, revealing neurodegenerative changes before traditional tests indicate impairment.

For the often treatment-resistant pain of neuropathic conditions, the meta-analysis includes updated evidence for both pharmacologic and neuromodulatory interventions.

The adjusted dosing for donanemab in early AD reduced ARIA-E risk by 41% compared to the original dosing, without compromising efficacy.

The Fujirebio in-vitro diagnostic has shown positive and negative predictive values of 92% and 97%, respectively, for early AD detection and will be offered by end of summer.

The StateViewer clinical decision support system could help expand access to specialist-level insights in clinics that lack neurology expertise, according to researchers.

The adjuvanted RSV vaccine, in particular, was associated with a 29% reduction in the risk of dementia in the subsequent 18 months, a University of Oxford study found.

Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.

Primary care clinicians are generally the first clinical contact for older adults with early signs of dementia. Our survey uncovered 5 primary challenges to being in that role.

The FDA cleared Happy Ring, a wearable device for at-home diagnosis of sleep disorders, enhancing access to vital sleep health solutions.

The superior tolerability and efficacy of the CGRP-targeting atogepant supports recent calls from the AHS to consider the class as first-line preventive therapy for migraine.